These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 26109320)

  • 1. Bacteriophages and bacteriophage-derived endolysins as potential therapeutics to combat Gram-positive spore forming bacteria.
    Nakonieczna A; Cooper CJ; Gryko R
    J Appl Microbiol; 2015 Sep; 119(3):620-31. PubMed ID: 26109320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogens.
    Fischetti VA
    Int J Med Microbiol; 2010 Aug; 300(6):357-62. PubMed ID: 20452280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LysPBC2, a Novel Endolysin Harboring a Bacillus cereus Spore Binding Domain.
    Kong M; Na H; Ha NC; Ryu S
    Appl Environ Microbiol; 2019 Mar; 85(5):. PubMed ID: 30552194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect of Bacteriophage Preparations on Intracellular Killing of Bacteria by Phagocytes.
    Jończyk-Matysiak E; Łusiak-Szelachowska M; Kłak M; Bubak B; Międzybrodzki R; Weber-Dąbrowska B; Żaczek M; Fortuna W; Rogóż P; Letkiewicz S; Szufnarowski K; Górski A
    J Immunol Res; 2015; 2015():482863. PubMed ID: 26783541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases.
    Matsuzaki S; Rashel M; Uchiyama J; Sakurai S; Ujihara T; Kuroda M; Ikeuchi M; Tani T; Fujieda M; Wakiguchi H; Imai S
    J Infect Chemother; 2005 Oct; 11(5):211-9. PubMed ID: 16258815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacteriophages, phage endolysins and antimicrobial peptides - the possibilities for their common use to combat infections and in the design of new drugs.
    Mirski T; Lidia M; Nakonieczna A; Gryko R
    Ann Agric Environ Med; 2019 Jun; 26(2):203-209. PubMed ID: 31232046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacteriophage endolysins as a potential weapon to combat
    Mondal SI; Draper LA; Ross RP; Hill C
    Gut Microbes; 2020 Nov; 12(1):1813533. PubMed ID: 32985336
    [No Abstract]   [Full Text] [Related]  

  • 8. Lysins as a powerful alternative to combat Bacillus anthracis.
    Nakonieczna A; Abramowicz K; Kwiatek M; Kowalczyk E
    Appl Microbiol Biotechnol; 2024 Jun; 108(1):366. PubMed ID: 38850320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The First Paenibacillus larvae Bacteriophage Endolysin (PlyPl23) with High Potential to Control American Foulbrood.
    Oliveira A; Leite M; Kluskens LD; Santos SB; Melo LD; Azeredo J
    PLoS One; 2015; 10(7):e0132095. PubMed ID: 26167894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bacteriophage lysins: progress and perspective--a review].
    Wang Y; Lu C
    Wei Sheng Wu Xue Bao; 2009 Oct; 49(10):1277-81. PubMed ID: 20069871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phage therapy: facts and fiction.
    Skurnik M; Strauch E
    Int J Med Microbiol; 2006 Feb; 296(1):5-14. PubMed ID: 16423684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacteriophage endolysins--current state of research and applications.
    Loessner MJ
    Curr Opin Microbiol; 2005 Aug; 8(4):480-7. PubMed ID: 15979390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacteriophage endolysins as a novel class of antibacterial agents.
    Borysowski J; Weber-Dabrowska B; Górski A
    Exp Biol Med (Maywood); 2006 Apr; 231(4):366-77. PubMed ID: 16565432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant bacteriophage lysins as antibacterials.
    Fenton M; Ross P; McAuliffe O; O'Mahony J; Coffey A
    Bioeng Bugs; 2010; 1(1):9-16. PubMed ID: 21327123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacteriophage-derived endolysins to target gram-negative bacteria.
    Lai WCB; Chen X; Ho MKY; Xia J; Leung SSY
    Int J Pharm; 2020 Nov; 589():119833. PubMed ID: 32877733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From endolysins to Artilysin®s: novel enzyme-based approaches to kill drug-resistant bacteria.
    Gerstmans H; Rodríguez-Rubio L; Lavigne R; Briers Y
    Biochem Soc Trans; 2016 Feb; 44(1):123-8. PubMed ID: 26862197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Advantages and Challenges of Using Endolysins in a Clinical Setting.
    Murray E; Draper LA; Ross RP; Hill C
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33920965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breaking barriers: expansion of the use of endolysins as novel antibacterials against Gram-negative bacteria.
    Briers Y; Lavigne R
    Future Microbiol; 2015; 10(3):377-90. PubMed ID: 25812461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impacts of food matrix on bacteriophage and endolysin antimicrobial efficacy and performance.
    Shannon R; Radford DR; Balamurugan S
    Crit Rev Food Sci Nutr; 2020; 60(10):1631-1640. PubMed ID: 30880427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potential of bacteriophage endolysins for infections caused by Gram-positive bacteria.
    Liu H; Hu Z; Li M; Yang Y; Lu S; Rao X
    J Biomed Sci; 2023 Apr; 30(1):29. PubMed ID: 37101261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.